<?xml version='1.0' encoding='utf-8'?>
<document id="19496045"><sentence text="[Clinically relevant drug interactions with new generation antidepressants and antipsychotics]." /><sentence text="Because antidepressants and antipsychotics are commonly described in combination with drugs used to treat comorbid psychiatric or somatic disorders (e" /><sentence text="g" /><sentence text=" anxiolytics, mood stabilizers, cardiovascular drugs, antimicrobial agents), they may be involved in drug interactions" /><sentence text=" Furthermore, agents such as lithium and atypical antipsychotics may be used to augment the antidepressant response in cases of refractory depression"><entity charOffset="29-36" id="DDI-PubMed.19496045.s5.e0" text="lithium" /></sentence><sentence text=" Based on their mechanisms, drug-drug interactions can be classified either as pharmacokinetic or pharmacodynamic in nature" /><sentence text=" The well-documented risk of potentially harmful pharmacodynamic drug interactions with first-generation anti-depressants, e" /><sentence text="g" /><sentence text=" monoamine oxidase inhibitors (MAOIs), with regard to the induction of the serotonin syndrome, has contributed to a gradual decline in their use in clinical practise"><entity charOffset="1-10" id="DDI-PubMed.19496045.s9.e0" text="monoamine" /><entity charOffset="75-84" id="DDI-PubMed.19496045.s9.e1" text="serotonin" /><pair ddi="false" e1="DDI-PubMed.19496045.s9.e0" e2="DDI-PubMed.19496045.s9.e0" /><pair ddi="false" e1="DDI-PubMed.19496045.s9.e0" e2="DDI-PubMed.19496045.s9.e1" /></sentence><sentence text=" Second- and third-generation antidepressants have gradually replaced tricyclic antidepressants (TCAs) and MAOIs, mainly because of their improved tolerability and safety profile" /><sentence text=" The second- and third-generation antidepressants include selective serotonin reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs) and other compounds with different mechanisms of action"><entity charOffset="68-77" id="DDI-PubMed.19496045.s11.e0" text="serotonin" /><entity charOffset="107-116" id="DDI-PubMed.19496045.s11.e1" text="serotonin" /><entity charOffset="121-135" id="DDI-PubMed.19496045.s11.e2" text="norepinephrine" /><pair ddi="false" e1="DDI-PubMed.19496045.s11.e0" e2="DDI-PubMed.19496045.s11.e0" /><pair ddi="false" e1="DDI-PubMed.19496045.s11.e0" e2="DDI-PubMed.19496045.s11.e1" /><pair ddi="false" e1="DDI-PubMed.19496045.s11.e0" e2="DDI-PubMed.19496045.s11.e2" /><pair ddi="false" e1="DDI-PubMed.19496045.s11.e1" e2="DDI-PubMed.19496045.s11.e1" /><pair ddi="false" e1="DDI-PubMed.19496045.s11.e1" e2="DDI-PubMed.19496045.s11.e2" /></sentence><sentence text=" These drugs and also the majority of antipsychotics are metabolized in the liver by the cytochrome P450 (CYP) enzyme system" /><sentence text=" Therefore, the use of these compounds may be associated with clinically relevant pharmacokinetic interactions with other medications" /><sentence text=" The knowledge about the CYP metabolism of drugs may be used to guide the selection of an antidepressant or an anti-psychotic with a low drug-drug interaction potential for an individual patient" /><sentence text=" The aim of the present article is to review drug-interaction potentials with specific focus on second-generation antidepressants (SSRIs), newer antidepressants (SNRIs: venlafaxine and duloxetine; bupropion, mirtazapine, trazodone), novel atypical antidepressants (agomelatine), as well as new generation atypical antipsychotics (aripiprazole, paliperidone)"><entity charOffset="169-180" id="DDI-PubMed.19496045.s15.e0" text="venlafaxine" /><entity charOffset="185-195" id="DDI-PubMed.19496045.s15.e1" text="duloxetine" /><entity charOffset="197-206" id="DDI-PubMed.19496045.s15.e2" text="bupropion" /><entity charOffset="208-219" id="DDI-PubMed.19496045.s15.e3" text="mirtazapine" /><entity charOffset="221-230" id="DDI-PubMed.19496045.s15.e4" text="trazodone" /><entity charOffset="265-276" id="DDI-PubMed.19496045.s15.e5" text="agomelatine" /><entity charOffset="330-342" id="DDI-PubMed.19496045.s15.e6" text="aripiprazole" /><entity charOffset="344-356" id="DDI-PubMed.19496045.s15.e7" text="paliperidone" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e0" e2="DDI-PubMed.19496045.s15.e0" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e0" e2="DDI-PubMed.19496045.s15.e1" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e0" e2="DDI-PubMed.19496045.s15.e2" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e0" e2="DDI-PubMed.19496045.s15.e3" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e0" e2="DDI-PubMed.19496045.s15.e4" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e0" e2="DDI-PubMed.19496045.s15.e5" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e0" e2="DDI-PubMed.19496045.s15.e6" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e0" e2="DDI-PubMed.19496045.s15.e7" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e1" e2="DDI-PubMed.19496045.s15.e1" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e1" e2="DDI-PubMed.19496045.s15.e2" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e1" e2="DDI-PubMed.19496045.s15.e3" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e1" e2="DDI-PubMed.19496045.s15.e4" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e1" e2="DDI-PubMed.19496045.s15.e5" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e1" e2="DDI-PubMed.19496045.s15.e6" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e1" e2="DDI-PubMed.19496045.s15.e7" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e2" e2="DDI-PubMed.19496045.s15.e2" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e2" e2="DDI-PubMed.19496045.s15.e3" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e2" e2="DDI-PubMed.19496045.s15.e4" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e2" e2="DDI-PubMed.19496045.s15.e5" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e2" e2="DDI-PubMed.19496045.s15.e6" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e2" e2="DDI-PubMed.19496045.s15.e7" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e3" e2="DDI-PubMed.19496045.s15.e3" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e3" e2="DDI-PubMed.19496045.s15.e4" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e3" e2="DDI-PubMed.19496045.s15.e5" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e3" e2="DDI-PubMed.19496045.s15.e6" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e3" e2="DDI-PubMed.19496045.s15.e7" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e4" e2="DDI-PubMed.19496045.s15.e4" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e4" e2="DDI-PubMed.19496045.s15.e5" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e4" e2="DDI-PubMed.19496045.s15.e6" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e4" e2="DDI-PubMed.19496045.s15.e7" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e5" e2="DDI-PubMed.19496045.s15.e5" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e5" e2="DDI-PubMed.19496045.s15.e6" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e5" e2="DDI-PubMed.19496045.s15.e7" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e6" e2="DDI-PubMed.19496045.s15.e6" /><pair ddi="false" e1="DDI-PubMed.19496045.s15.e6" e2="DDI-PubMed.19496045.s15.e7" /></sentence><sentence text="" /></document>